Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMN AMN Healthcare Services	$20.03 -2.0%	$20.64	$17.45 ▼ $70.07	$766.85M	0.16	913,607 shs	594,475 shs
DNLI Denali Therapeutics	$14.42 +3.5%	$13.84	$10.57 ▼ $33.33	$2.09B	1.49	1.12 million shs	2.08 million shs
LTH Life Time Group	$29.86 +2.4%	$30.09	$16.81 ▼ $34.99	$6.55B	1.86	1.71 million shs	1.35 million shs
XENE Xenon Pharmaceuticals	$30.46 -0.8%	$32.83	$26.74 ▼ $46.00	$2.34B	1.21	547,389 shs	636,103 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMN AMN Healthcare Services	+0.73%	-4.77%	-3.86%	-21.93%	-63.16%
DNLI Denali Therapeutics	-0.21%	+5.45%	-15.27%	-14.54%	-31.65%
LTH Life Time Group	-1.50%	+1.63%	-9.67%	-9.15%	+69.61%
XENE Xenon Pharmaceuticals	+2.16%	+4.28%	-19.75%	-17.35%	-20.08%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMN AMN Healthcare Services	4.2573 of 5 stars	3.1	2.0	0.8	4.3	1.9	1.7	1.9
DNLI Denali Therapeutics	4.3888 of 5 stars	4.5	1.0	0.0	4.7	3.0	2.5	0.0
LTH Life Time Group	3.4845 of 5 stars	2.3	4.0	0.0	0.0	3.4	1.7	3.1
XENE Xenon Pharmaceuticals	3.5881 of 5 stars	4.5	4.0	0.0	0.0	3.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMN AMN Healthcare Services	2.25	Hold	$32.08	60.18% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.71	133.80% Upside
LTH Life Time Group	2.62	Moderate Buy	$35.92	20.31% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$54.82	79.97% Upside

Current Analyst Ratings Breakdown

Latest AMN, XENE, DNLI, and LTH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	LTH Life Time Group	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$45.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/14/2025	XENE Xenon Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$55.00
5/13/2025	AMN AMN Healthcare Services	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$30.00 ➝ $25.50
5/13/2025	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $47.00
5/13/2025	XENE Xenon Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$58.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$53.00 ➝ $53.00
5/13/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00 ➝ $55.00
5/13/2025	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$60.00 ➝ $55.00
5/9/2025	LTH Life Time Group	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$33.00 ➝ $34.00
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00

(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMN AMN Healthcare Services	$2.85B	0.27	$5.61 per share	3.57	$18.56 per share	1.08
DNLI Denali Therapeutics	$330.53M	6.34	N/A	N/A	$7.42 per share	1.94
LTH Life Time Group	$2.73B	2.40	$1.78 per share	16.76	$11.48 per share	2.60
XENE Xenon Pharmaceuticals	$7.50M	311.64	N/A	N/A	$14.18 per share	2.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMN AMN Healthcare Services	-$146.98M	-$4.33	N/A	8.28	N/A	-4.93%	15.22%	4.72%	8/14/2025 (Estimated)
DNLI Denali Therapeutics	-$145.22M	-$2.67	N/A	N/A	N/A	N/A	-32.94%	-30.04%	7/30/2025 (Estimated)
LTH Life Time Group	$76.06M	$0.96	43.28	28.44	0.81	5.67%	6.42%	2.14%	8/7/2025 (Estimated)
XENE Xenon Pharmaceuticals	-$182.39M	-$3.23	N/A	N/A	N/A	N/A	-24.69%	-23.68%	8/14/2025 (Estimated)

Latest AMN, XENE, DNLI, and LTH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	XENE Xenon Pharmaceuticals	-$0.90	-$0.83	+$0.07	-$0.83	$1.64 million	$7.50 million
5/8/2025	Q1 2025	AMN AMN Healthcare Services	$0.19	$0.45	+$0.26	-$0.03	$670.08 million	$689.53 million
5/8/2025	Q1 2025	LTH Life Time Group	$0.27	$0.39	+$0.12	$0.34	$684.06 million	$706.04 million
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMN AMN Healthcare Services	$1.20	5.99%	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
LTH Life Time Group	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMN AMN Healthcare Services	1.49	1.09	1.18
DNLI Denali Therapeutics	N/A	9.98	9.98
LTH Life Time Group	0.64	0.59	0.46
XENE Xenon Pharmaceuticals	N/A	22.21	22.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMN AMN Healthcare Services	99.23%
DNLI Denali Therapeutics	92.92%
LTH Life Time Group	79.40%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
AMN AMN Healthcare Services	0.93%
DNLI Denali Therapeutics	12.50%
LTH Life Time Group	8.70%
XENE Xenon Pharmaceuticals	5.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMN AMN Healthcare Services	4,230	38.29 million	37.72 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	132.55 million	Optionable
LTH Life Time Group	30,000	219.42 million	181.10 million	Optionable
XENE Xenon Pharmaceuticals	210	76.73 million	72.03 million	Optionable

AMN, XENE, DNLI, and LTH Headlines

Recent News About These Companies

Inhibitor Therapeutics (OTCMKTS:INTI) and Xenon Pharmaceuticals (NASDAQ:XENE) Financial Comparison

June 4 at 2:07 AM | americanbankingnews.com

Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference

June 3 at 4:01 PM | globenewswire.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

June 2 at 4:23 AM | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Bank of America Corp DE

May 31, 2025 | marketbeat.com

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 30, 2025 | globenewswire.com

Xenon Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:XENE)

May 30, 2025 | marketbeat.com

Ameriprise Financial Inc. Increases Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 28, 2025 | marketbeat.com

Woodline Partners LP Makes New $1.57 Million Investment in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27, 2025 | marketbeat.com

Two Sigma Investments LP Increases Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 27, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Position Lifted by Millennium Management LLC

May 26, 2025 | marketbeat.com

Northern Trust Corp Raises Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 26, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Acquired by Two Sigma Advisers LP

May 25, 2025 | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Stock Rating Lowered by StockNews.com

May 23, 2025 | marketbeat.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Given Consensus Recommendation of "Buy" by Brokerages

May 23, 2025 | marketbeat.com

Fair Value analysis proves accurate as XENE drops 37% from February 2024 peak

May 21, 2025 | investing.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Sold by Vestal Point Capital LP

May 21, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Sells 117,919 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 21, 2025 | marketbeat.com

Ensign Peak Advisors Inc Sells 136,970 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 19, 2025 | marketbeat.com

Leerink Partnrs Issues Optimistic Forecast for XENE Earnings

May 18, 2025 | marketbeat.com

Sphera Funds Management LTD. Acquires Shares of 52,097 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 18, 2025 | marketbeat.com

Polar Capital Holdings Plc Increases Stock Position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

May 17, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AMN, XENE, DNLI, and LTH Company Descriptions

AMN Healthcare Services NYSE:AMN

$20.03 -0.41 (-2.01%)

As of 03:59 PM Eastern

AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions. The Nurse and Allied Solutions segment offers travel nurse staffing, labor disruption staffing, local staffing, international nurse and allied permanent placement, and allied staffing solutions. The Physician and Leadership Solutions segment provides locum tenens staffing, healthcare interim leadership staffing, executive search, and physician permanent placement solutions. The Technology and Workforce Solutions segment offers language services, vendor management systems, workforce optimization, and outsourced solutions. The company also provides allied health professionals, such as physical therapists, respiratory therapists, occupational therapists, medical and radiology technologists, lab technicians, speech pathologists, rehabilitation assistants, and pharmacists. It offers its services under the brands, including AMN Healthcare, Nursefinders, HealthSource Global Staffing, O'Grady Peyton International, Connetics, Medical Search International, DRW Healthcare Staffing, and B.E. Smith. AMN Healthcare Services, Inc. was founded in 1985 and is headquartered in Dallas, Texas.

Denali Therapeutics NASDAQ:DNLI

$14.42 +0.49 (+3.52%)

As of 04:00 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Life Time Group NYSE:LTH

$29.86 +0.69 (+2.37%)

As of 03:59 PM Eastern

Life Time Group Holdings, Inc. provides health, fitness, and wellness experiences to a community of individual members in the United States and Canada. It primarily engages in designing, building, and operating of sports and athletic, professional fitness, family recreation, and spa centers in a resort-like environment, principally in suburban and urban locations of metropolitan areas. The company also offers fitness floors with equipment, locker rooms, group fitness studios, indoor and outdoor pools, bistros, indoor and outdoor tennis courts, pickleball courts, basketball courts, LifeSpa, LifeCafe, and childcare and Kids Academy learning spaces. In addition, its Life Time Digital provides live streaming fitness classes, remote goal-based personal training, nutrition and weight loss support, curated award-winning health, and fitness and wellness content. The company is also involved in media activities, conducting athletic events, and provision of related services. It operates various centers, including ground leases. The company was formerly known as LTF Holdings, Inc. and changed its name to Life Time Group Holdings, Inc. in June 21, 2021. Life Time Group Holdings, Inc. was founded in 1992 and is headquartered in Chanhassen, Minnesota.

Xenon Pharmaceuticals NASDAQ:XENE

$30.46 -0.26 (-0.85%)

As of 04:00 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time